On Monday, June 8, at SLEEP 2015 in Seattle, a special discussion group will be held to review the preliminary findings of the SERVE-HF study, which indicate that there is an increased risk of cardiovascular death with ASV treatment for patients with central sleep apnea syndrome; symptomatic, chronic heart failure; and a reduced left ventricular ejection fraction. The special discussion group, ASV Therapy for CSA Patients with Heart Failure: SERVE-HF Results, will be held from 10:30 a.m. to 12 p.m. in Room 6E of the Washington State Convention Center.
